More than 400 clinicians and researchers meet to discuss Cachexia, Sarcopenia and Wasting Disorders. Lisa Niemi-Swayze will be the keynote speaker at the Society's Charity Dinner.
The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is pleased to announce that the 6th International Cachexia Conference will be held in Milan, Italy on 8-10 December 2011.
Over 400 participants will gather from more than 25 countries around the world to listen to presentations given by more than 60 internationally recognized experts in the field. A multidisciplinary approach will be taken, covering Wasting Disorders such as Sarcopenia and Cachexia.
A SCWD Charity Dinner will also take place on 9 December 2011.
Ms. Lisa Niemi Swayze, the wife of Patrick Swayze, will participate in person to share how her life was impacted by the disease.
About the SCWD:
The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) was set up in 2008 as a nonprofit organization 501 (c) (3). Its mission is to increase awareness about Sarcopenia, Cachexia and Wasting Disorders, and to educate healthcare providers through the organization of educational activities with a multidisciplinary approach. The SCWD also tries to raise public awareness about the burden of these Wasting Disorders.
Cachexia is a complex metabolic syndrome associated with underlying illness and characterized by weight loss. Cachexia is common and occurs in over 50% of cancer patients and 90% of patients with pancreatic cancer. It represents a significant adverse health care issue and challenge for an increasing number of patients, their relatives and the medical teams who care for them.
Cachexia affects patients in a wide range of chronic medical conditions such as AIDS, cancer, chronic heart failure, chronic lung disease, liver cirrhosis, renal failure, rheumatoid arthritis, and sepsis. Its disease process involves a complex interaction between the disease and the body.
Cachexia is infrequently identified or diagnosed, and rarely treated As the treatment of diseases such as cancer, CHF, COPD, HIV infection, and kidney disease becomes increasingly effective, the diagnosis and treatment of Cachexia associated with these diseases will become important goals to improve morbidity, mortality, and particularly, the quality of life. Active research is being developed in this field.
For additional information, contact Yann Colardelle of MedEd Global Solutions at:
Tel: +33142530303 - Fax: +33142530302